Literature DB >> 23068961

C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.

Michinori Takabe1, Tomokazu Matsuda, Yushi Hirota, Naoko Hashimoto, Tomoaki Nakamura, Kazuhiko Sakaguchi, Wataru Ogawa, Susumu Seino.   

Abstract

The amelioration of glucose tolerance by liraglutide was associated with a significant improvement of early insulin-response during OGTT. The serum C-peptide response to glucagon challenge strongly correlated with the improvement of the early insulin-response. The C-peptide response to glucagon challenge would be useful to predict therapeutic response to liraglutide.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23068961     DOI： 10.1016/j.diabres.2012.09.036

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  6 in total

1.  A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.

Authors:  Takeshi Yamamoto; Tomoyasu Fukui; Akiko Higuchi; Makoto Ohara; Toshiyuki Hayashi; Tsutomu Hirano
Journal:  Diabetol Int       Date:  2016-04-13

2.  Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes.

Authors:  Kenjiro Imai; Tetsuro Tsujimoto; Atsushi Goto; Maki Goto; Miyako Kishimoto; Ritsuko Yamamoto-Honda; Hiroshi Noto; Hiroshi Kajio; Mitsuhiko Noda
Journal:  Diabetol Metab Syndr       Date:  2014-10-15       Impact factor: 3.320

Review 3.  A Practical Review of C-Peptide Testing in Diabetes.

Authors:  Emma Leighton; Christopher Ar Sainsbury; Gregory C Jones
Journal:  Diabetes Ther       Date:  2017-05-08       Impact factor: 2.945

4.  Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist.

Authors:  Hiroshi Miura; Naokazu Muramae; Kenta Mori; Kazunori Otsui; Kazuhiko Sakaguchi
Journal:  Cureus       Date:  2022-06-13

Review 5.  C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.

Authors:  Ernesto Maddaloni; Geremia B Bolli; Brian M Frier; Randie R Little; Richard D Leslie; Paolo Pozzilli; Raffaela Buzzetti
Journal:  Diabetes Obes Metab       Date:  2022-06-28       Impact factor: 6.408

6.  Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.

Authors:  Angus G Jones; Timothy J McDonald; Beverley M Shields; Anita V Hill; Christopher J Hyde; Bridget A Knight; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2015-08-04       Impact factor: 19.112
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.